[68Ga] Ga-PSMA versus [18F] PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review …
L Evangelista, T Maurer, H van der Poel… - European Urology …, 2022 - Elsevier
Context In the past 10 yr, several agents based on prostate-specific membrane antigen
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
68Ga-PSMA-11 PET/CT versus 68Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
R Huang, Y Li, H Wu, B Liu, X Zhang, Z Zhang - Frontiers in Oncology, 2023 - frontiersin.org
Purpose Our aim was to conduct a meta-analysis and systematic review in order to compare
the diagnostic efficacy of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in patients …
the diagnostic efficacy of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in patients …
The role of PSMA PET/CT in the primary diagnosis and follow-up of prostate cancer—a practical clinical review
AR Lisney, C Leitsmann, A Strauß, B Meller… - Cancers, 2022 - mdpi.com
Simple Summary The combination of positron emission tomography (PET)-diagnostics with
ligands binding to the prostate-specific membrane antigen (PSMA) has been a diagnostic …
ligands binding to the prostate-specific membrane antigen (PSMA) has been a diagnostic …
18F‐PSMA‐1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta‐Analysis
M Ferrari, G Treglia - Contrast Media & Molecular Imaging, 2021 - Wiley Online Library
Background. Prostate‐specific membrane antigen‐(PSMA‐) targeted agents labeled with
fluorine‐18 (18F) have recently become available to evaluate patients with biochemical …
fluorine‐18 (18F) have recently become available to evaluate patients with biochemical …
Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State
L Saule, M Radzina, M Liepa, L Roznere, A Lioznovs… - Diagnostics, 2022 - mdpi.com
Background: Early diagnosis of recurrent prostate cancer is a cornerstone for further
adequate therapy planning. Therefore, clinical practice and research still focuses on …
adequate therapy planning. Therefore, clinical practice and research still focuses on …
Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence …
TM Morgan, SA Boorjian, MK Buyyounouski… - Journal of …, 2024 - journals.lww.com
Purpose: The summary presented herein covers recommendations on salvage therapy for
recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for …
recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for …
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy
S Adebahr, A Althaus, S Scharl, I Strouthos… - European journal of …, 2024 - Springer
Aim The optimal management for early recurrent prostate cancer following radical
prostatectomy (RP) in patients with negative prostate-specific membrane antigen positron …
prostatectomy (RP) in patients with negative prostate-specific membrane antigen positron …
Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer
S Harsini, P Martineau, S Plaha, H Saprunoff, C Chen… - Cancer Imaging, 2024 - Springer
Background Prostate-specific membrane antigen (PSMA) positron emission
tomography/computed tomography (PET/CT) is becoming standard of care for men with …
tomography/computed tomography (PET/CT) is becoming standard of care for men with …
Impact of piflufolastat F‐18 PSMA PET imaging on clinical decision‐making in prostate cancer across disease states: A retrospective review
AT Arafa, A Jain, P Skrobanek, B Humphrey… - The …, 2023 - Wiley Online Library
Abstract Introduction Piflufolastat F‐18 (18F‐DCFPyL) prostate‐specific membrane antigen
(PSMA) positron emission tomography (PET) imaging is approved by the US food and drug …
(PSMA) positron emission tomography (PET) imaging is approved by the US food and drug …
[HTML][HTML] Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial
J Martinez, K Subramanian, SH Castellanos… - Translational …, 2023 - Elsevier
The clinical utility of gallium 68 (68 Ga)-PSMA PET for the diagnosis and management of
prostate cancer is driven in part by radioisotope availability and production costs. This study …
prostate cancer is driven in part by radioisotope availability and production costs. This study …